The Catch-22 in Global Health Finance: Why Medical Oxygen is the Test Case for Turning Aid into Investment
By most measures, medical oxygen in sub-Saharan Africa isn’t an investable market. As Alex Losneanu and Jason Houdek at Oxygen CoLab explain, providing medical oxygen is capital-intensive and operationally demanding. That means small- and medium-sized oxygen suppliers typically stall out or get absorbed into grant-funded programs instead of becoming commercially viable, and funders conclude that these SMEs are too fragile to justify the investment risk. They argue that this conclusion is wrong, and also self-fulfilling, reinforcing a Catch-22 that exists across global health. They share findings from a supplier mapping project that show how emerging business models are enabling oxygen SMEs to scale, and propose three shifts in how catalytic capital can be designed to support these and other businesses across the global health sector.
